JP3 Measurement, LLC (FTK) Earnings Call Transcript & Summary

May 19, 2020

New York Stock Exchange US Materials Chemicals earnings 41 min

Earnings Call Speaker Segments

Danielle Allen

executive
#1

Thanks, and good morning, everybody. We’re glad you could join us. With me on the call are John Gibson, our Chairman, Chief Executive Officer and President; Matt Thomas, who serves as President of JP3; and Elizabeth Wilkinson, our Chief Financial Officer. During this call, we’ll begin with prepared comments about the business and the quarter’s results. After that, we’ll take whatever questions you may have. Our earnings announcement for the first quarter came out yesterday, and you can find it on our Web site. A webcast of today’s call is underway, and a replay will be posted on our Web site as well. We also have an investor presentation tied to the announced acquisition that will accompany this earnings call. Please be aware that anything we say today about projections or what we expect in the future counts as forward-looking statements. Such statements carry a number of risks and uncertainties, and many of those are outside our control. Those risks and uncertainties could lead actual events to differ materially from what we currently expect. We encourage listeners to look over our earnings release and the risk factors covered in our SEC filings; in addition, please see the reconciliations included in our earnings press release, since management might discuss non-GAAP metrics during this call; with all that said, I’m pleased to hand things over to John.

John Gibson

executive
#2

Thank you, Danielle. I hope everybody is doing well and staying safe, and I want to express my appreciation to each of our team members, the Flotekers, for the dedication and effort they've shown our company through this difficult period. The beginning of 2020 has truly been extraordinary — the oil and gas sector saw too much oil supply and insufficient storage capacity, along with demand being destroyed by the worldwide response to COVID-19. Because of COVID-19, we had to shift toward leading from a distance, with Teams and Zoom taking over the majority of my days and the days of all our staff too. What's remarkable is that this has led to reduced reliance on physical offices and in-person interaction, and an absolute focus on our mission. The current market situation has produced so much disorder that many avenues for growth, both organic and inorganic, have appeared. We've taken a careful approach in evaluating those possibilities, wanting to lessen how much we depend on rig count, lessen our reliance on the U.S. unconventional sector, and build an offering in the digital transformation space — specifically chemistry in the cloud. Through this evaluation, we're thrilled to announce our purchase of JP3, a data and analytics technology firm experiencing rapid growth, which broadens our company's business mix and assists us in reshaping our company for the next phase of profitable growth. On today's call, I'd like to start by discussing the acquisition news we released today; a presentation has been posted that we'll refer to this morning, and we're happy to have Matt Thomas, who serves as President of JP3, with us on the call to share his perspective on the deal too. After that, we'll cover the continuing cost actions tied to near-term difficulties and our longer-term objectives for getting our cost structure to the right size, and then talk briefly about our Q1 financial results. Let me start with an overview and the reasoning behind today's news about our purchase of JP3. We bought 100% ownership of JP3 through a cash and stock deal, consisting of $25 million in cash and 11.5 million shares of Flotek's stock, plus another $5 million earn-out tied to appreciation of Flotek's stock, and the deal was completed yesterday, May 18. This acquisition brings strong strategic and financial advantages, as we've laid out on Slide 4. To start, the deal broadens Flotek's business across every segment of the hydrocarbon value chain. Next, JP3 is a rapidly growing business with considerable upside. During the last four years, JP3 has achieved impressive revenue growth of 58% with more than 60 clients. There's also a market opportunity worth roughly $1 billion each year in the U.S. by itself, with substantial growth potential beyond the U.S. that we can capture by utilizing Flotek's international market access. Third, Flotek's solid liquidity can drive growth by speeding up JP3's data as a service, or DaaS, product offerings. And last, JP3's ongoing shift toward the DaaS business model will produce a high-margin recurring revenue stream that remains sustainable even when commodity markets are more volatile. Our goal is to be the platform that maximizes profitability across the entire chain, from the reservoir all the way to where refined products end up. Flotek's breakthrough chemistry has boosted ultimate recovery reserves, and JP3's data adds a new dimension to that goal by quantifying how effective the injected chemistry is. Beyond that, JP3's data offers reach and power that extend much further. Refinery optimization calls for consistent feedstock, and until JP3's data solutions came along, buyers relied on API gravity as a stand-in for hydrocarbon composition. Once JP3 systems are deployed, the crude's actual composition can be identified right at the wellhead, which lets refiners buy oil that fits the refinery's design or blend output from many locations to produce the feedstock that yields the greatest profit. In addition, knowing which cut refineries value most—like the components that end up in gasoline or diesel—will let us engineer reservoir chemicals so producers can recover more of the most valuable molecules. Put most simply, we can start refining inside the reservoir. In essence, the more we understand about hydrocarbons, the more efficient, clean, safe and profitable our industry becomes. I'll hand things over to Matt Thomas, President of JP3, for a few comments. We're thrilled to have you with us, Matt—please go ahead and tell us about JP3.

Matt Thomas

executive
#3

Thanks, John. I'm delighted to be here. Being part of the Flotek family is genuinely thrilling for us, and we can see numerous paths by which JP3 is now positioned well to speed up its growth. Because Flotek has a solid liquidity standing and worldwide market reach, JP3 can continue building on a record of double-digit expansion and quickly advance the shift already underway toward recurring revenue through a DaaS model. Our clients will keep seeing better profitability as we help them get the most value from their hydrocarbons by leveraging data produced by our real-time optical analyzer systems. In oil and gas, JP3 stands as the top analyzer and data delivery platform. And we were thrilled when our technologies gained recognition as the industry benchmark earlier this year, through adoption of the Midstream Industry Association's GPA 2119 Standard. Our line of advanced Verax analyzers first came to market in 2012, giving customers real-time composition and physical properties for their liquid and natural gas hydrocarbon streams all the way from the wellhead to the fuel terminal, while cost-effectively surmounting what traditional technologies could not do. Together with our Viper cloud analytics platform, shown on Slide 5 of the deck that accompanies this call, we now deliver data to everyone from small independent producers to midstream MLPs to major refineries throughout North America. Even while the industry currently faces disruption, the proprietary data platform from JP3 lets our clients bring in more revenue and earn higher profits from the product streams they already have. Now, with Flotek's capital supporting us, we can grow our DaaS sales and marketing activities, speed up work on next generation technologies, and open international sales possibilities by tapping Flotek's global reach. As Slide 6 shows, JP3's data products add value throughout the industry, including upstream crude analysis at the wellhead, doing away with outdated API gravity proxies, and bringing production contract pricing into line with finished goods value. In midstream, that means gas plant balancing, optimization and give-away reduction, and in refining it means optimization of crude feedstock blends and distillation tower performance. To show further how powerful the data from our analytics systems is, I'd like to call attention to one downstream distribution application of special significance. Last week, we were happy to announce a joint initiative with Phillips 66 to launch a revolutionary data service solution in the refined fuels market, intended to substantially boost profits for refined fuel producers, transporters and distribution terminal operators. First, a bit of context, using Slide 11 to illustrate. As refined fuel product streams depart a refinery, they move through a common pipeline carrying gasoline, jet fuel, diesel and other products to their end markets. Natural mixing takes place between adjacent batches of these fuels, and this interface transportation mixture, or transmix, has to be separated and sent to special holding tanks for reprocessing, which means net losses for operators. Our Verax data platform is now helping companies lower the amount of product downgrades caused by transmix and raise profitability by as much as 50%. Also, automation and control solutions rely by nature on real-time information that our data platform generates. The creative joint marketing agreement JP3 signed with Phillips 66 covering DaaS sales and refined fuels confirms how strong our platform is and how much profit customers are gaining by using our data. Phillips 66 holds an already solid place in the refined fuels market, and working together we can grow our market share substantially and grab greater value in this area. Thanks to the strength of JP3 technology platforms plus the performance data Philips will supply, a massive opportunity exists to grow our footprint in the downstream distribution market; and that is merely one illustration of how clients of ours employ our real-time data to alter their business's financials. To sum up, JP3 delivers a differentiated technology platform featuring hundreds of demonstrated applications, marketplace growth, and a clear runway to a $1 billion domestic addressable market. And now, as part of Flotek, JP3 can speed up our top-line growth and recurring revenue model considerably. Major opportunities exist inside the oil and gas industry, and beyond that our data platform scales to other industrial markets too. We are eager to join the Flotek team and to help build shareholder value. And now I'll hand it back over to John. Thanks, John.

John Gibson

executive
#4

Thank you so much, Matt. Alright, let's turn to the next topic, and that truly concerns responding to what's happening in the market along with costs, in light of the tough industry backdrop we've confronted. A number of cost initiatives have been put in place by us to assist in lessening exposure throughout the company while boosting efficiency and effectiveness. We stay disciplined with our controls on expenses so that our financial flexibility can be strengthened. Near-term steps taken lately include cutting the salaries of the executive team, lowering fees paid to the Board of Directors, and shrinking the Board's size from seven members down to five, along with trimming headcount and scaling back discretionary spending throughout the whole organization. Decisions like these were not made easily, yet they are required given the market environment today. Looking ahead, our focus is on derisking the business, since the fundamentals of the oil and gas industry have shifted considerably. We've been actively searching out further chances to lower costs, allowing us to return to profitability over the medium term. During the prior quarter, we talked about our priority of right sizing and repricing the relationship we have with Florida Chemical Company. Working alongside FCC in February, we amended the terpene supply agreement, and that will let us meaningfully enhance our cost and cash flow throughout the contract's term and helps us manage inventory better. With those changes in place, we can now compete more effectively in the marketplace when it comes to procurement within specialized chemistry portfolios; this likewise creates openings to chase new routes to market, for instance by leveraging proprietary technology for data analysis across the full hydrocarbon stream stemming from our acquisition of JP3; through these fresh opportunities, operating costs can be lowered and our profitability maximized. As Q1 2020 played out, it exposed major disruption in the environment we operate in. An impairment charge of 57.5 million was recorded by us in the first quarter tied to impairment of property, plant and equipment, right to use assets and intangibles. Various steps have also been taken by us to strengthen the company's financial position as we bring our workforce and operations in line with the activity level we're witnessing in the current environment, which will let us operate more effectively in a completely different world. In addition, Elizabeth will cover the consolidation of our office spaces. Finally, we'd also like to briefly spotlight our team's work giving back to the community and our customers. Watching Flotek unite to leverage surplus capacity at our manufacturing facilities and our chemistry expertise to make alcohol based hand sanitizer makes me incredibly proud. Because of that, we produced roughly 12,000 gallons of hand sanitizer, donated to first responders, hospitals, schools, homeless shelters and senior residential communities in the communities we serve. With that, I'll hand things over to Elizabeth for a deeper look at our financial results. Elizabeth?

Elizabeth Wilkinson

executive
#5

Thanks, John. Just like we said on earlier calls, the financial tables included with our press release show the operations of our CICT segment as a discontinued operation across all periods. Today, my discussion will center on quarterly results for our continuing operations, which take in the Energy Chemistry business — we'll call that ECT — along with our supporting research and innovation and corporate functions. As we go through our financial results, revenue for the first quarter came in at $19.4 million, versus $43.3 million in the same period a year ago, though it was broadly in line on a sequential basis with the 19.5 million posted in the prior quarter. In the first quarter of 2020, ECT's operating expenses came to 22.8 million. That compares to 44 million during Q1 of the prior year — a year-over-year decrease of 48%. During that first quarter of 2020, a $2.3 million charge was recorded, which reflected a loss tied to terpene purchase commitments as well as an added reserve against terpene inventory currently on hand. Because of the supply chain and operational efficiency improvements made during 2019, along with the amendment to our terpene contract that we negotiated in February, we'll be in a position to actively manage inventory down to lower levels moving forward. In Q1 2020, corporate G&A dropped to 4.5 million, down from 7.3 million during the same period a year before. That decline came from cutting headcount and trimming other expenses, plus a smaller severance charge — 0.5 million this quarter against 1.6 million in the prior-year quarter. Turning to our results, we posted a loss from continuing operations of $64 million for the first quarter of 2020, which works out to a $1.07 loss per diluted share. In last year's first quarter, that figure stood at a loss of 15.2 million, or $0.26 loss per diluted share. A $57.5 million impairment charge was part of that $64 million loss, tied to us lowering our long-term forecast because of what's happening in today's economic and political climate. For the first quarter, adjusted EBITDA came in at a loss of $6.5 million, an improvement over the $7.6 million loss we posted a year ago. That better adjusted EBITDA number largely reflects a much smaller workforce along with major cost cuts in freight, equipment, and travel and entertainment. Our table in the release has additional details. Now on the balance sheet, we remain happy with how strong our position is. By the end of Q1 2020 — specifically March 31 — our cash and equivalents totaled $80.3 million, we carried no outstanding debt, and the balance sheet showed $6.6 million held in escrow, which represents what we claim as the remaining portion of the indemnity escrow tied to selling Florida Chemical to Archer Daniels Midland, or ADM. Also, on that same March 31 date, we booked a $6.1 million tax receivable tied to a refund under the CARES Act provision that lengthens the period for carrying back net operating losses. Additionally, in Q1, leadership finalized plans to consolidate our Houston offices, and all corporate personnel will move into our Houston Global Research and Innovation Centre by the end of this month. In connection with that relocation, we negotiated an early termination of the lease for our Houston headquarters at a favorable discount, which is anticipated to generate annual savings for the company of approximately $900,000 from mid-2020 through mid-2023. Having said that, we're prepared to take your questions. Operator?

Daniel Burke

analyst
#6

John, to start, congratulations on the transaction. I've got a few things I want to ask about JP3, though perhaps I'll begin with one about the business as it stands, since the speed of this downturn in the oilfield — especially on the completion side — has been quite steep. Is there anything you can tell us about how the second and third quarters are shaping up from the inside, and about your capacity to steer toward a cash neutral position across that stretch? Liquidity, after all, is in short supply at the moment.

John Gibson

executive
#7

Honestly, my objective of reaching breakeven, which I mentioned three months ago, remains unchanged. So we're putting a lot of effort into the cost side of that equation. Cost of goods sold naturally falls when your activity levels drop as sharply as these have. Beyond that, we're controlling the remaining costs as tightly as we possibly can. On Q2 and Q3 — well, Q2, I should say, we're in the thick of it right now, and I don't anticipate market activity picking up in Q2, and none of our rivals are suggesting any pickup either. Among our customers, Daniel, we are observing a bit of stabilization, because prices have recovered from an absurdly low point to a level that's at least bearable, and they'll keep producing, whereas earlier we had started to believe that shutting in wells would become the dominant activity. My expectation is that shut-ins will ease somewhat, people will carry on producing, and storage capacity never reached a critical threshold. So the market we have is acceptable; it isn't strong. We'll therefore control our costs accordingly. We'll keep working at bringing them down. As for Q3, I lack a crystal ball. That makes forecasting COVID-19 and its effects difficult for me, and the same goes for Q4, since it's hard for us to determine just how quickly the virus will surge again once fall arrives; in our view, that will influence activity more than oil and gas prices will. That's where I expect we'll run into trouble getting people back to work. Still, as our figures show, we eliminated a great deal of cost; we're down 47.5% year-over-year in our costs, which takes in cost of goods sold, and it demonstrates genuine dedication to this effort, which we'll sustain going forward. Glad to take another question. Daniel, I went on too long with that answer.

Daniel Burke

analyst
#8

No, that's useful, John. Let me switch over to JP3, definitely an intriguing transaction; and let me pose one, or maybe a couple, quick questions. Given that JP3 leans toward midstream and downstream, I'd guess the effect on their operations during this year has been limited, but could you provide any sense or insight into how things have gone for them across recent months?

John Gibson

executive
#9

Clearly, things eased somewhat because of COVID, yet business remains solid and there's plenty of potential — during diligence, I spoke with several of their clients who are dedicated not just to current activities, but also to applications that would let us grow the business, which explains why we're so enthusiastic about it. I don't expect them to be hit the way drill bits are for the remainder of the year. Consequently, a key element here involved shifting from a focus on rig count and drill bits to possessing availability across the entire market — we believe midstream, downstream and distribution networks will remain robust with reduced volatility. Thus, we're quite eager to lower risk regarding where we see the business heading in the coming years through the acquisition of JP3.

Daniel Burke

analyst
#10

All right, and then thinking about JP3, perhaps just across this first period from when it started up to around the close of this year, it looks like it ought to be a fairly capital-light operation, yet you all are wanting to put money into it, you want to encourage its expansion. What I'm asking is, does this operation use up capital during the rest of this year, or does it produce cash during the rest of this year?

John Gibson

executive
#11

I really don't view it as producing cash or earnings, Daniel, it's a chance to invest, a tiny firm with an enormous opportunity for growth that can generate considerable gross margin down the road; so the investments you mention are the correct lens for it. This isn't a capital-intensive operation. Yet it's one that has been understaffed when it comes to sales, and I'm hopeful we can bring on additional sales personnel who will keep that momentum going or perhaps even spark it. We also believe there are a few other moves we can make that will generate use cases for our operation at Flotek too, so that we can — put simply, we want to understand just how efficiently and effectively we treat reservoirs; so if we send down 1000 gallons and recover nothing, we ought to have sent more. If we send down 1000 gallons and then recover 500 gallons of that, we sent down 100% too much; and so how can we truly be sure we're applying the correct treatment? We believe this will in fact create some use cases for us on the reservoir chemistry side too. So we're hoping they will pull our operation forward and set us apart from rivals as well. But cash light? Indeed. The investment opportunity here concerns fast growth; and that's where our attention will go, they've achieved 58% growth year-over-year. We're going to find out whether we can take the right step to speed that up by strengthening our international sales push along with our domestic sales push too.

Brian Bode

analyst
#12

I was just curious whether you might talk about what other options exist at the corporate level for allocating capital, compared with repurchasing shares or pursuing growth possibilities such as JP3.

John Gibson

executive
#13

Honestly, Brian, it's likely that not everyone will be pleased. Still, my attention isn't on buying back stock. What I care about is the stock going up; this morning, as a management team here, we discussed concentrating on expanding our business and increasing our equity value, which would let us complete additional acquisitions of this kind. Here's how I see it. You can find some outstanding companies with rapid growth and strong margins in that arena, yet no IPO market currently exists for them. They align very closely with chemistry, and we're able to offer them a platform essentially to become publicly traded. So by using our equity value to help move those businesses into our area — almost the way you'd picture us going back — our aim is to bring them aboard, and therefore my focus is on growing share value and on the capacity to genuinely construct a platform of fast-growing enterprises and fast-growing activities moving forward.

Brian Bode

analyst
#14

All right, that's helpful context. In what way did you folks come across JP3, or in what way did they come across you, and perhaps keeping that in mind, might you discuss the sort of present pipeline or present opportunities currently being assessed?

John Gibson

executive
#15

Okay, this is a bit of a revealing point for me, I suppose, as you're aware, prior to becoming part of Flotek, my role was in investment banking with TPH, working in their emerging technologies — energy technologies group, and it was there that we spotted JP3. And honestly, I can say I regarded it as an excellent company back when I was with the bank. Once I arrived at Flotek, among the entire portfolio, it truly aligned with Flotek most effectively in diversification, which brings me to the reality that I needed to ensure everybody understood I'm not conflicted on this. I opted to take — I didn't opt to take, I ought never take, but I opted to take no bonus from this deal from TPH. And so there will be no compensation there. And it was truly about ensuring I had no conflicts whatsoever, but I've been aware of this company for a minimum of a year; and actually, a number of the customers we spoke with, our customers, I brought JP3 to, so I've effectively been on their sales staff for roughly 12 months and grasp the technology, so it wasn't a thing that merely emerged over the last few months, it's a thing I've had knowledge of for likely a year.

Peter Rabover

analyst
#16

I assume you picked up some kind of deal here. I'd like to follow up on what was asked before, just a bit further. John, you mentioned that your emphasis is on opportunities with high growth. So I'm curious whether there's actually any growth happening in this business. And what makes you confident that growth is going to materialize, considering how much turmoil there is in oil and gas right now and the possibility that it could take years to sort itself out?

John Gibson

executive
#17

That's a really good question. During my opening remarks, I mentioned that we're working to diversify away from dependence on rig count, or on drill bits. My belief is that the key properties in the Permian, along with the Boston and others, are going to rebound, since those can be produced at a profit even when prices are lower, though it's possible not every bit of acreage returns in the same manner. So I anticipate some softening in what we consider, clearly, a strong conventional market. Even so, we believe it remains a solid market. It will be a reduced market, and we were determined to bring in assets that face no limits on expansion. We continue to think demand for energy will be enormous, and we believe operators are going to keep producing, plus solutions that boost midstream profitability, such as the transmix solution we're developing alongside Phillips 66. The way you deal with powers at refineries, all of these represent markets that will simply keep expanding; that's why we wanted to shift into a market with high growth. Another excellent point here, and I'll return to what Daniel asked. Regarding capital, the company we acquired doesn't need research and development to bring a product to market, since they already have a commercial product. That's why we're pleased this is a matter of needing strong sales efforts; it isn't a situation where I'm running an R&D operation, putting capital into a business hoping to make it succeed. It functions right now, we're going to deliver it right now, and that's why we went through with the acquisition. So for us, we see that as a genuinely high growth portion of the market. And on the other side, we simply want to ensure we maintain capital discipline and cost discipline, so that we can make that segment of the business profitable too.

Peter Rabover

analyst
#18

Hi folks, sorry about that. I muted myself, and after I did, the line dropped. Anyway, I wanted to circle back to that question regarding the acquisitions — considering the amount of cash you were sitting on and what a bloodbath the last few months were, my guess is you probably fielded hundreds of calls from folks similar to JP3. So I'm wondering, what set them apart from all the rest? Were they far and away the best option? And how many additional chances like that do you expect to come across? Then I had one more thing on the financial side. A — John Gibson Peter Rabover Glad to take that one. What's interesting is we evaluated quite a few businesses, including one in this same area that took a different route to measuring chemistry in real time. Our view is that if your goal is generating profit, you can't manage something you aren't able to measure. So we examined a handful of other businesses. I'm getting some feedback here. So we reviewed multiple companies. As I mentioned just a moment ago, the very first one we reviewed was actually a big company. Fantastic technology, fantastic team, but our sense was it would take somewhere between $10 million and $15 million of investment to bring the product to market. It wasn't market-ready. After reviewing that, we came together as a management team — and our purpose isn't venture capital investing, our purpose is putting money into growth markets where a product already exists — so we walked away from it. Even though, if you're technically minded, you'd say wow, this is impressive; it was impressive, yet it lacked that instant sales opportunity that JP3 offered. So you're absolutely right. My phone rings nonstop. Plenty of folks are buried in heavy debt and need a way out, so they see our capital and want us to essentially clear their debt and combine with their business. We've seen chances to pursue other technologies, but honestly, we reached out to JP3; JP3 didn't reach out to us. And so, Matt, I mean, I'm certain you've gotten other calls too since I left the bank some time ago, but we actively went after JP3 because we recognized it was such an ideal match. Matt, isn't that right?

Matt Thomas

executive
#19

Yes. And let me just add — appreciate the question, Peter. And expanding on what John said, from where we sit, we saw this as an excellent fit for several reasons. To start with, the strong liquidity position Flotek provides can definitely speed up our growth. Being able to reach global markets we currently lack access to, that strikes us as quite appealing; on top of that, this management group is really strong and brings an impressive record of results. As you likely are aware, John has built a successful history with acquisitions — I believe somewhere in the range of 25 to 30 deals over his career — and once we examined that, we concluded this represents the growth stage for JP3 that we had been seeking; so it genuinely shaped up as an appealing match for us.

Peter Rabover

analyst
#20

All right. Thanks. And I suppose — I realize you haven't put out financials and so forth, but what I'm really wondering is how you expect your cash situation to end up given this investment, and, I don't know, does this investment lose money, what about cash flow? How much cash do you figure you'll have to put into sales personnel, and whatever detail you can share, I'd really be grateful.

John Gibson

executive
#21

Clearly, we laid out 25 million, so you should figure that 25 million is going to leave our cash position. As far as the investment goes, we're going to push hard to try to remain inside our cost. With the goal — again, there's still a goal I want to reach, getting us to breakeven this year. I haven't pulled back from that despite how awful the market is. I'll tell you that I watched the hurdle rise a great deal across the last couple of months; when I made that comment in Q1, I had no clue I'd be facing a 7.5 foot high jump rather than a 2.5 foot high jump; but we're zeroed in on it, we will locate the money to boost their sales. Some of that is training a portion of our sales staff, but some of it is bringing in their salespeople, which is a different market; and they already have a team at JP3 and we're already interviewing some senior people that we believe would make a big difference in catalyzing this, and we reached out to them early on in the process to see whether or not they too, agreed with what we saw as a market; so it's a bit of validation to see experienced salespeople in the DaaS market look at this and consider joining because they see this as a huge growth platform and opportunity for them as well.

Vishal Mishra

analyst
#22

Hello John and Matt, congrats on the transaction. Your 10-K includes that remark, and John, during the Q1 call you mentioned that should drilling drop enormously, it ought not to affect your capacity to get out there and make a difference on wells already finished; and I realize, that was another period, one that was, nearly falling, yet still 40s and 20s and early 30s. Also, CapEx budgets got reduced. So the world has changed now. Still, I want to ask—could you revisit that point? Specifically, the idea that this shouldn't get in the way of your ability to go out and deliver results on wells that are already completed. Or maybe, given COVID, that's just too difficult a question to respond to. Even so, anything you can share about your ability to take share in wells that have already been drilled would be great.

John Gibson

executive
#23

Vishal, your audio was breaking up a bit, so it sounded like you were asking how we'll grow share within our core business. And in that context, staying nimble and lean really does matter. James Silas has joined us as well. I'm not sure — Mark is on the line about our sales. We had a meeting, and the takeaway was: in a market like this one, adaptability is essential. Beyond lifting output during that first phase of production, what more can our chemistry accomplish? Another area where we think we can create substantial value is enhanced oil recovery. In reservoirs like these — where wells are already drilled, the production infrastructure already exists, and that represents capital — there's a huge chance to apply chemicals for enhanced oil recovery, or enhanced product recovery, from those reservoirs. That's why our attention is directed there — we want to be certain we're delivering what we think customers will require over the next several months, in this situation. Even without drilling, they'll keep producing, and they want their output to be higher. Consider recovery factors: for unconventional reservoirs, initial production sits somewhere between 4% and 8%. If we could achieve something similar to what's done in the North Sea — though actually double it — lifting recovery from 48% to 8% to 16% across the industry, that represents an enormous gain for unconventional operators. So right now we're examining the way chemicals affect AUR. We believe that will genuinely strengthen our main business moving ahead, along with the possibilities tied to shut-ins. The thing is, a shut-in is the step you take if you believe the market won't recover, whereas AUR work involves figuring out what to do when you expect the market to return and rebound strongly.

John Gibson

executive
#24

Okay, first off, I'd like to express my appreciation to each of you for being here with us today. The purchase of JP3 has us really enthusiastic, and our belief is that it will speed up our expansion while complementing Flotek's chemistry applications nicely. Also, the power of our liquidity foundation and access to markets is going to be utilized as we move ahead. Our view is that we are setting this company up for a prosperous and bright tomorrow. And we genuinely value our shareholders' backing. Through this acquisition, hopefully you can see that your input has been heard — if you told me where you believe the future lies. As we proceed into the next phase of growth, we'll keep providing updates on our ongoing work. Hopefully, you'll hear from me prior to the following quarter. Have a great day, everyone.

Danielle Allen

executive
#25

Thank you.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete JP3 Measurement, LLC transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to JP3 Measurement, LLC earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in JP3 Measurement, LLC or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.